APX-3330 is under clinical development by Ocuphire Pharma and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase II drugs for Diabetic Macular Edema have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APX-3330’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APX-3330 is under development for the treatment of solid tumors including pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma, endometrial cancer, melanoma, chronic hepatitis C, prostate cancer and colorectal cancer, diabetic macular edema, non proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), hematological cancers including acute lymphoblastic leukemia, malignant peripheral nerve sheath tumor (MPNST), laser-induced choroidal neovascularization, tuberous sclerosis complex (TSC), inflammation, inflammatory bowel disease, wet age-related macular degeneration, gall bladder cancer, hepatocellular cancer, bladder cancer and ovarian cancer. It is a new chemical entity and is administered orally as a tablet. The drug candidate acts by targeting Ref-1 and TNF synthesis.
It was also under development for the treatment of hepatic failure and chemotherapy-induced peripheral neuropathy, non proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR).
Ocuphire Pharma overview
Ocuphire Pharma is an ophthalmic biopharmaceutical company that develops and commercializes medicines to treat eye disorders. It is investigating Nyxol, a preservative-free ophthalmic solution for dim light and night vision disturbances (DLD), reversal of Mydriasis (RM), presbyopia, and glaucoma. The company is also evaluates APX3330, an oral pill targeting diabetic retinopathy (DR) and macular edema (DME); and APX2009 drug against wet age-related macular degeneration (WAMD). Ocuphire Pharma seeks to work in partnership with pharmaceutical companies for development and commercialization of its drug candidates. It markets its product under the brand Nyxol. Ocuphire Pharma is headquartered in Farmington Hills, Michigan, the US.
For a complete picture of APX-3330’s drug-specific PTSR and LoA scores, buy the report here.